Britain and America have secured a major bilateral deal that will preserve zero import taxes on British medicine exports being sold in the US market.
Agreement Details of the Pact
As part of the deal, the UK has agreed to boost spending on medicines through the National Health Service (NHS). This move guarantees that tariffs on these vital products will stay at nothing for a period of 36 months.
This development comes after previous statements to hike duties on patented drug imports, with figures mentioned up to 100%.
"This agreement between the UK bolsters the worldwide climate for cutting-edge drugs and brings long-overdue balance to U.S.–U.K. pharmaceutical trade," a statement noted.
Economic Impact
Pharmaceuticals represent one of the the United Kingdom's biggest goods shipped to the United States, which is by far the largest destination for large companies like GSK and AstraZeneca.
Statistics reveal that in the year to the end of the third quarter, the UK shipped medicines totaling £11.1bn to the US. This value represented a significant portion of total UK exports in that span.
"This guarantee safeguards jobs, stimulates capital expenditure and paves the way for the UK to emerge as a international leader for biotech and pharma," a government official remarked.
Key NHS Changes
The deal includes several notable commitments from the British government:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it deems new treatments to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a target to raise overall public funding on treatments from 0.3% of GDP to 0.6% over the coming ten years.
- Rebate Cap: The sum manufacturers must return to the NHS to prevent overspending will be limited at 15%. Last year, refunds were more than 20%.
Broader Context
The deal follows a protracted row between the sector and the UK government over spending levels and regulatory access.
These tensions were exacerbated by assertions that US customers were charged a premium for the same drugs than people in the Britain and the EU.
In recent months, several significant drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar investments have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS had to spend more on medicines, noting that its expenditure on drugs had shrunk as a proportion of its total funding over the past decade.
